Repligen | RGEN - Cost Of Sales


Repligen reported $94.09M in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
Agilent USD 845M 7M Mar/2026
Align Technology USD 298.76M 4.74M Jun/2026
Bio Techne USD 103.13M 1.47M Mar/2026
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Bruker USD 443.6M 84.4M Mar/2026
Charles River Laboratories USD 716.51M 5.76M Mar/2026
Danaher USD 2.65B 294M Jun/2026
Dentsply International USD 453M 65M Mar/2026
General Electric Aerospace USD 8.89B 736M Jun/2026
Henry Schein USD 2.3B 145M Mar/2026
Illumina USD 389M 19M Jun/2026
IQVIA Holdings USD 3.22B 141M Jun/2026
Mettler Toledo International USD 396.52M 14.4M Jun/2026
Myriad Genetics USD 63M 1.1M Dec/2025
OraSure Technologies USD 15.43M 113K Dec/2025
Pacific Biosciences Of California USD 28.9M 10M Dec/2025
Pfizer USD 4.09B 498M Jun/2026
Repligen USD 94.09M 8.12M Jun/2026
Revvity USD 323.46M 26.93M Mar/2026
Standard Biotools USD 9.84M 2.58M Mar/2026
Thermo Fisher Scientific USD 7.54B 577M Jun/2026
Waters USD 725M 350.06M Mar/2026
West Pharmaceutical Services USD 543.1M 5.4M Jun/2026